irisin glp-1 The role of in exercise-induced muscle and metabolic health: a narrative review | Naunyn-Schmiedeberg's Archives of Pharmacology Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics
Description
Peak GLP-1 increases were significantly higher (~32%) after RYGB at both follow-ups (p<0.05)
We categorised participants based on their response: HbA1c reduction only, weight loss only, both or neither
Clinical studies have provided strong evidence about GLP-1 safety
For anyone tired of starting over every January
The significant year-over-year (YoY) jump in GLP-1 coverage among the largest companies signals a key shift: the employer debate is moving from whether to cover weight loss drugs to how to do so sustainably.
Obesity has further been associated with higher disease activity and reduced time to flare
